Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Amgen (AMGN) Stock Forecast & Price Target

Amgen logo
$439.26 -8.02 (-1.79%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$442.00 +2.74 (+0.62%)
As of 10/23/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
3
Hold
16
Buy
11

Based on 30 Wall Street analysts who have issued ratings for Amgen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 30 analysts, 3 have given a sell rating, 16 have given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for AMGN.

Consensus Price Target

$389.71
-11.28% Downside
According to the 30 analysts' twelve-month price targets for Amgen, the average price target is $389.71. The highest price target for AMGN is $500.00, while the lowest price target for AMGN is $200.00. The average price target represents a forecasted downside of -11.28% from the current price of $439.26.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for AMGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Amgen and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMGN Analyst Ratings Over Time

TypeCurrent Forecast
10/25/25 to 10/25/26
1 Month Ago
9/25/25 to 9/25/26
3 Months Ago
7/27/25 to 7/27/26
1 Year Ago
10/25/24 to 10/25/25
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
5 Buy rating(s)
Hold
16 Hold rating(s)
15 Hold rating(s)
15 Hold rating(s)
11 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$389.71$383.46$356.62$300.38
Forecasted Upside-11.28% Downside-7.51% Downside-5.22% Downside2.95% Upside
Consensus RatingHoldHoldHoldHold

AMGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AMGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Amgen Stock vs. The Competition

TypeAmgenHealthcare CompaniesBroader Market
Consensus Rating Score
2.30
2.32
2.53
Consensus RatingHoldHoldModerate Buy
Predicted Upside-11.28% Downside1,400.11% Upside16.92% Upside
News Sentiment Rating
Positive News

See Recent AMGN News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/23/2026
Oppenheimer Holdings, Inc. logo
Oppenheimer
3 of 5 stars
Jay Olson
5 of 5 stars
Reiterated RatingOutperform
10/21/2026
Barclays PLC logo
Barclays
3 of 5 stars
Emily Field
Not Rated
Boost TargetEqual Weight$380.00 ➝ $400.00-8.87%
10/13/2026
Guggenheim logo
Guggenheim
5 of 5 stars
Vamil Divan
Vamil Divan
4 of 5 stars
Lower TargetNeutral$388.00 ➝ $378.00-9.48%
10/12/2026Lower TargetMarket Perform$450.00 ➝ $415.00-0.17%
10/12/2026Lower TargetEqual Weight$435.00 ➝ $430.00+3.65%
10/9/2026Boost TargetBuy$430.00 ➝ $470.00+14.32%
10/8/2026 UpgradeBuy (B) ➝ Buy (B+)
10/8/2026Boost TargetOutperform$400.00 ➝ $430.00+5.49%
10/7/2026Boost TargetHold$362.00 ➝ $380.00-8.06%
10/7/2026Lower TargetEqual Weight$362.00 ➝ $359.00-13.08%
10/5/2026Boost TargetNeutral$400.00 ➝ $440.00+9.17%
9/28/2026Boost TargetOutperform$450.00 ➝ $500.00+19.68%
9/23/2026Reiterated RatingHold$410.00-0.06%
9/10/2026DowngradeBuy ➝ Hold$445.00 ➝ $425.00+8.62%
8/20/2026Boost TargetOverweight$427.00 ➝ $457.00+3.31%
8/19/2026Boost TargetBuy$375.00 ➝ $460.00+7.04%
8/18/2026Boost TargetNeutral$303.00 ➝ $352.00-16.07%
8/7/2026Boost TargetNeutral$345.00 ➝ $405.00+0.04%
8/6/2026Boost TargetMarket Perform$335.00 ➝ $345.00-15.41%
8/5/2026Boost TargetBuy$420.00 ➝ $452.00+11.26%
8/5/2026 Boost TargetUnderperform$215.00 ➝ $230.00-41.12%
8/5/2026 Boost TargetUnderperform$312.00 ➝ $317.00-18.85%
8/5/2026Boost TargetHold$366.00 ➝ $384.00-1.70%
6/5/2026 Set Target$389.00+9.79%
5/13/2026 Lower TargetOutperform$410.00 ➝ $390.00+17.59%
5/7/2026 UpgradeHold ➝ Strong-Buy
5/5/2026 Reiterated RatingBuy ➝ Hold
3/5/2026Reiterated RatingMarket Perform$355.00-3.43%
2/18/2026 Boost TargetSell$180.00 ➝ $200.00-46.43%
2/5/2026 Boost TargetHold$285.00 ➝ $295.00-19.79%
11/10/2025 Boost Target$335.00 ➝ $364.00+13.68%
9/3/2025Initiated CoverageMarket Perform
6/24/2025 Reiterated RatingOutperform
3/5/2025 Set Target$294.00-10.47%
11/15/2024Initiated CoveragePeer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:38 PM ET.


Should I Buy Amgen Stock? AMGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 23, 2026. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com.

Amgen
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Amgen Inc.:

  • Amgen Inc. recently reported strong third-quarter results, beating analyst expectations with earnings per share of $6.29 against a consensus of $5.62 and revenue of $10.05 billion, which exceeded the estimated $9.43 billion, demonstrating robust fundamental performance and year-over-year revenue growth of 9.5%.
  • The company has raised its full-year 2026 earnings guidance to a range of $22.30 to $23.50 per share, signaling management confidence in continued growth, while the stock currently trades at $439.26, reflecting a significant 55% increase from its October lows and highlighting strong investor momentum.
  • Amgen Inc. provides a stable income stream with a dividend yield of 2.30%, having recently paid a quarterly dividend of $2.52 per share, which offers a reliable return for income-focused investors despite the stock's recent price appreciation.
  • Recent positive clinical developments, including Phase III data for Tezspire in eosinophilic esophagitis and updates on Bemarituzumab in gastric cancer, suggest potential for portfolio expansion and new revenue streams in respiratory-immunology and oncology sectors.
  • With a low beta of 0.41, Amgen Inc. exhibits lower volatility compared to the broader market, making it a defensive holding that may provide stability during periods of market uncertainty while still participating in the biotechnology sector's growth.

Amgen
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Amgen Inc. for these reasons:

  • The stock's current price of $439.26 is significantly above the consensus price target of $387.93, suggesting that the stock may be overvalued relative to Wall Street's average expectations, which could limit future upside potential.
  • Amgen Inc. carries a high debt-to-equity ratio of 4.44, indicating substantial leverage that could pose financial risks if interest rates remain elevated or if the company faces unexpected operational challenges, potentially impacting its ability to service debt.
  • Recent insider activity shows a trend of selling, with senior executives like Rachna Khosla and Nancy A. Grygiel reducing their holdings in August 2026, which may signal a lack of confidence in the stock's near-term performance or a desire to lock in gains.
  • The company's dividend payout ratio stands at 62.65%, which is relatively high and may limit the amount of cash available for reinvestment in research and development or acquisitions, potentially constraining long-term growth opportunities.
  • Despite recent gains, the stock has experienced volatility, including a notable gap down of 28.33 points in September 2026, and the consensus rating remains a "Hold," indicating that analysts are divided on the stock's future direction and potential risks.

AMGN Forecast - Frequently Asked Questions

According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for Amgen is $389.71, with a high forecast of $500.00 and a low forecast of $200.00.

30 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 3 sell ratings, 16 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.

According to analysts, Amgen's stock has a predicted downside of -11.28% based on their 12-month stock forecasts.

Over the previous 90 days, Amgen's stock had 2 upgrades and 2 downgrades by analysts.

Analysts like Amgen less than other "healthcare" companies. The consensus rating score for Amgen is 2.30 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how AMGN compares to other companies.


MarketBeat monitors more than a dozen sources for Amgen analyst ratings, with the most recent rating issued on 10/23/2026.
From Our Partners